Summit Creek Advisors LLC Buys 146 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Summit Creek Advisors LLC increased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.3% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 47,808 shares of the company’s stock after acquiring an additional 146 shares during the period. Medpace comprises approximately 2.1% of Summit Creek Advisors LLC’s investment portfolio, making the stock its 22nd largest holding. Summit Creek Advisors LLC owned 0.15% of Medpace worth $15,883,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Pallas Capital Advisors LLC raised its stake in Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after buying an additional 2,101 shares during the period. Barclays PLC raised its stake in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after buying an additional 8,275 shares during the period. Sanctuary Advisors LLC raised its stake in Medpace by 20.5% in the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock valued at $1,738,000 after buying an additional 844 shares during the period. Loomis Sayles & Co. L P raised its stake in Medpace by 7.2% in the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock valued at $68,696,000 after buying an additional 13,880 shares during the period. Finally, Cerity Partners LLC raised its stake in Medpace by 18.7% in the third quarter. Cerity Partners LLC now owns 61,890 shares of the company’s stock valued at $20,659,000 after buying an additional 9,741 shares during the period. Institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird upped their price objective on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Trading Up 1.4 %

Medpace stock opened at $324.23 on Monday. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The stock’s 50 day moving average is $337.72 and its 200-day moving average is $339.77. The company has a market capitalization of $9.88 billion, a price-to-earnings ratio of 25.67, a PEG ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.